Schedule

Day 1

13:00 - 15:00

Registration

Tea, coffee and poster set up.

15:00 - 15:15

Welcome and opening remarks

To be given by Andrew Chalmers.

Session 1

Chair: Paul Whitley, University of Bath, UK

15:15 - 15:35

Mathias Uhlén, SciLifeLab, Sweden

Validation of antibodies in the open access Human Protein Atlas resource

15:35 - 15:55

Jürgen Schmitz, Miltenyi Biotec, Germany

15:55 - 16:15

Asel Sartbaeva, University of Bath/EnsiliTech, UK

16:30 - 18:00

Drinks reception

Posters and sponsors' exhibition.

Day 2

09:00 - 09:30

Open

Tea, coffee and pastries

Session 2

Chair: Carly Dix, AstraZeneca, UK

09:30 - 09:50

Ibolya Kepiro, National Physical Laboratory (NPL), UK

09:50 - 10:10

Antony Wood, Cell Signaling Technology, USA

De-risking the data: The critical importance of validation in the age of multiplex and spatial biology

10:10 - 10:30

Lena D'Hooghe, UCB, UK

Validation and characterisation of UCB discovered antibodies

10:30 - 11:00

Break

Tea, coffee, posters and sponsors' exhibition

Session 3

Chair: Sam Heywood, UCB, UK

11:00 - 11:20

Katarzyna Kmiecik, Alchemab, UK

Mining for therapeutic antibodies from disease-resilient individuals

11:20 - 11:40

Kevin Harvey, Aviva Systems Biology, USA

Use of high throughput SPR to characterize antibodies to common cancer biomarkers

11:40 - 12:00

Pierre Cosson, University of Geneva, Switzerland

ABCD: One database to list them all

12:00 - 13:00

Lunch

Lunch, posters and sponsors' exhibition

Session 4

Chair: Giovanna Roncador, CNIO, Spain

13:00 - 13:20

Anthony Couvillon, Mercy BioAnalytics, USA

Development of a liquid-biopsy, early-stage cancer diagnostic assay using highly validated, commercially available antibodies.

13:20 - 13:40

Kit Nazor, Proteintech, USA

Development of ultra high-plex multiomic assays.

13:40 - 14:00

Dean Clift, MRC Laboratory of Molecular Biology, UK

Trim-Away: targeted protein degradation using off-the-shelf antibodies

14:00 - 15:30

Poster session

Tea, coffee, posters and sponsors' exhibition

15:30 - 17:00

Discussion forum

All delegates are invited to ask questions and join in the discussion

Part 1: What can suppliers do to improve antibody validation?

Supplier panel

  • Junli Yu, Abcam, China
  • Matt Baker, Thermo Fisher Scientific, USA
  • Kristopher Nazor, Proteintech, USA
  • Antony Wood, Cell Signaling Technology, USA
  • Alexander Ball, GeneTex, USA

Part 2: What can end users do to improve antibody validation?

End user panel

  • Dean Clift, MRC LMB, UK
  • Andrea Radtke, NIAID (NIH), USA
  • Anthony Couvillon, Mercy BioAnalytics, USA
  • Katarzyna Kmiecik, Alchemab Therapeutics, UK
  • Elena Ivanova, Regeneron, USA
19:30 - late

Conference dinner

Conference social event (Hilton, Bath)

Day 3

09:00 - 09:30

Open

Tea, coffee and pastries

Session 5

Chair: Andrew Buchanan, AstraZeneca, UK

09:30 - 09:50

Peter McPherson, McGill University, Canada

YCharOS: antibody characterization through open science

09:50 - 10:10

Will Howat, Abcam, UK

Abcam Validation & Quality 2.0

10:10 - 10:30

Andrea Radtke, NIAID (NIH), USA

Accelerating discovery together: A community approach to multiplexed tissue imaging

10:30 - 11:00

Break

Tea, coffee, posters and sponsors' exhibition

Session 6

Chair: Amanda Williams, UCB Pharma, UK

11:00 - 11:20

David Piper, Thermo Fisher Scientific, USA

Accelerating life science research with Thermo Fisher Scientific’s specificity verified antibodies.

11:20 - 11:40

Elena Ivanova, Regeneron, USA

Antibody validation in preclinical histology core (PHC)

11:40 - 12:00

Nicola Lawson, AstraZeneca, UK

Closing remarks

To be given by Andrew Chalmers